Advertisement

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Published:November 24, 2022DOI:https://doi.org/10.1016/j.thromres.2022.11.016

      Abstract

      Background

      Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide.

      Methods

      GARFIELD-VTE is a prospective, non-interventional observational study of real-world treatment practices. We aimed to capture the 36-month clinical outcomes of 10,679 patients with objectively confirmed VTE enrolled between May 2014 and January 2017 from 415 sites in 28 countries.

      Findings

      A total of 6582 (61.6 %) patients had DVT alone, 4097 (38.4 %) had PE ± DVT. At baseline, 98.1 % of patients received anticoagulation (AC) with or without other modalities of therapy. The proportion of patients on AC therapy decreased over time: 87.6 % at 3 months, 73.0 % at 6 months, 54.2 % at 12 months and 42.0 % at 36 months. At 12-months follow-up, the incidences (95 % confidence interval [CI]) of all-cause mortality, recurrent VTE and major bleeding were 6.5 (7.0–8.1), 5.4 (4.9–5.9) and 2.7 (2.4–3.0) per 100 person-years, respectively. At 36-months, these decreased to 4.4 (4.2–4.7), 3.5 (3.2–2.7) and 1.4 (1.3–1.6) per 100 person-years, respectively. Over 36-months, the rate of all-cause mortality and major bleeds were highest in patients treated with parenteral therapy (PAR) versus oral anti-coagulants (OAC) and no OAC, and the rate of recurrent VTE was highest in patients on no OAC versus those on PAR and OAC. The most frequent cause of death after 36-month follow-up was cancer (n = 565, 48.6 %), followed by cardiac (n = 94, 8.1 %), and VTE (n = 38, 3.2 %). Most recurrent VTE events were DVT alone (n = 564, 63.3 %), with the remainder PE, (n = 236, 27.3 %), or PE in combination with DVT (n = 63, 7.3 %).

      Interpretation

      GARFIELD-VTE provides a global perspective of anticoagulation patterns and highlights the accumulation of events within the first 12 months after diagnosis. These findings may help identify treatment gaps for subsequent interventions to improve patient outcomes in this patient population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • ISTH Steering Committe for World Thrombosis Day
        Thrombosis: a major contributor to the global disease burden.
        J. Thromb. Haemost. 2014; 12: 1580-1590
        • Raskob G.E.
        • et al.
        Thrombosis: a major contributor to global disease burden.
        Arterioscler. Thromb. Vasc. Biol. 2014; 34: 2363-2371
        • Cohen A.T.
        • et al.
        Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.
        Thromb. Haemost. 2007; 98: 756-764
        • Kearon C.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Hokusai V.T.E.I.
        • et al.
        Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
        N. Engl. J. Med. 2013; 369: 1406-1415
        • Schulman S.
        • et al.
        Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
        Circulation. 2014; 129: 764-772
        • Bauersachs R.
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N. Engl. J. Med. 2010; 363: 2499-2510
        • Agnelli G.
        • et al.
        Oral apixaban for the treatment of acute venous thromboembolism.
        N. Engl. J. Med. 2013; 369: 799-808
        • Weitz J.I.
        Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
        Thromb. Haemost. 2016; 116: 1172-1179
        • Ageno W.
        Characteristics of Patients with Acute Venous Thromboembolism: Perspectives from the International, Observational, GARFIELD-VTE Registry.
        2018 (In preparation)
        • Schulman S.
        • Kearon C.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J. Thromb. Haemost. 2005; 3: 692-694
        • Bates S.M.
        • et al.
        Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e351S-e418S
        • Ageno W.
        • et al.
        Characteristics and Management of Patients with venous thromboembolism: the GARFIELD-VTE registry.
        Thromb. Haemost. 2019; 119: 319-327
        • Cohen A.T.
        • G.A
        • Bauersachs R.
        The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
        Thromb. Haemost. 2017; 11: 1326-1337
        • Registry
        R. Major bleeding and VTE recurrences.
        (Available from:)
        • Ahmed M.
        Blood thinners and gastrointestinal endoscopy.
        World J. Gastrointest. Endosc. 2016; 17: 584-590
        • Rebecca Caroline Barker B.B.F.
        Paul Marval Venous thromboembolism: risks and prevention.
        Contin. Educ. Anaesth. Crit. Care Pain. 2011; 11 (BMedSci BMBS FRCA): 18-23
        • Sardar P.
        • C.S
        • Mukherjee D.
        Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
        Drugs. 2013; 73: 1171-1182
        • Glynn R.J.
        • Rosner B.
        Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism.
        Am. J. Epidemiol. 2005; 162: 975-982
        • Prandoni P.
        • et al.
        An association between atherosclerosis and venous thrombosis.
        N. Engl. J. Med. 2003; 348: 1435-1441
        • Piazza G.
        • Goldhaber Samuel Z.
        Venous thromboembolism and atherothrombosis an integrated approach.
        Circulation. 2010; 121: 2146-2150
        • Kearon C.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Ageno W.
        • F.A
        • Haas S.
        • Weitz J.I.
        • Goldhaber S.Z.
        • Turpie A.G.G.
        • Goto S.
        • Angchaisuksiri P.
        • Dalsgaard Nielsen J.
        • Kayani G.
        • Schellong S.
        • Bounameaux H.
        • Mantovani L.G.
        • Prandoni P.
        • Kakkar A.K.
        Provoked versus unprovoked venous thromboembolism: findings from GARFIELD-VTE.
        Res. Pract. Thromb. Haemost. 2021; 20: 326-341
        • Sedgwick P.
        Prospective cohort studies: advantages and disadvantages.
        BMJ [Br. Med. J.]. 2013; 347f6726